190189-98-1

Usage

InChI:InChI=1/C11H15BrN2O2/c1-11(2,3)16-10(15)14-9-6-8(7-12)4-5-13-9/h4-6H,7H2,1-3H3,(H,13,14,15)

Upstream product

• 639091-75-1 methyl 2-[(tert-butoxycarbonyl)amino]isonicotinate 
• 6937-03-7 methyl 2-aminoisonicotinate 
• 13362-28-2 2-aminoisonicotinic acid 
• 506-68-3 bromocyane 
• 7732-18-5 water 
• 90101-20-5 tert-Butyl N-(4-methyl-pyridin-2-yl)carbamate 
• 305329-03-7 2-[N,N-bis(tert-butoxycarbonyl)amino]isonicotinic acid ethyl ester 
• 304873-62-9 (4-hydroxymethylpyridin-2-yl)carbamic acid tert-butyl ester 

Downstream Products

• 1126422-76-1 5-benzyloxy-1-(2-tert-butoxycarbonylamino-pyridin-4-ylmethyl)-3-(2-methoxy-pyridin-3-yl)-1H-indole-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN

A novel cyclic compound having a 4-pyridylalkylthio group having an (un) substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H; (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents -CO-, -COO-, -CONR 6- -SO2-, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFIa).

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the structure, for example, of STR1 for example STR2